Why Is Avacta Group PLC Up on 11 Nov 2026?

Avacta Group PLC shares rose 10.56% on 11 Nov 2026, with LSE:AVCT among the notable risers in the market snapshot. The move follows the company's half-year update, which outlined clinical progress across its pre|CISION peptide drug conjugate pipeline.

The company reported clinical proof of mechanism for its lead Phase 1 programme, AVA6103, together with a clean safety profile across the first three dose levels.

Further milestones are scheduled, including data presentations and candidate selection for its dual-payload programme.

About Avacta Group PLC

Avacta Group PLC develops pre|CISION peptide drug conjugates, which are designed to release cancer payloads selectively in tumours using fibroblast activation protein as the targeting mechanism.

The approach aims to deliver potent cancer medicines directly to the tumour environment. For LSE:AVCT, the pipeline of AVA6000, AVA6103 and AVA6207 represents the main driver of long-term development value.

AVA6103 Clinical Progress

AVA6103 is a fibroblast activation protein-enabled, controlled-release form of exatecan being studied in the Phase 1 FOCUS-01 trial. The company reported clinical proof of mechanism and pharmacokinetic data aligned with preclinical modelling, showing controlled release of exatecan for days after dosing.

Following an end-of-Phase 1 meeting, the US regulator agreed on certain elements of a pivotal trial design.

Upcoming Data Milestones

Initial efficacy data from AVA6103, including tumour biopsy data on drug retention, are expected in the first half of 2027.

Updated data for AVA6000, also known as faridoxorubicin, are due to be presented at the ESMO Congress in October 2026, while payload and clinical candidate selection for the dual-payload programme AVA6207 is expected in the fourth quarter of 2026.

Cash Position and Funding

Cash and equivalents were £20.27 million at 30 June 2026, and the company has said committed expenses provide a runway into early 2027.

Avacta raised £41.5 million over the preceding 18 months and has reduced the outstanding balance of its convertible bond.

Leadership and Partnering

Richard Hughes has taken up a non-executive chairman role, with a further non-executive director appointed as deputy chairman and senior independent director.

The company has described discussions with multiple parties on first, second and third-generation Assets as constructive.

The Peptide Drug Conjugate Approach

Peptide drug conjugates link a targeting element to a cancer-fighting payload so that the medicine is released where it is needed.

The aim is to improve the balance between effectiveness and tolerability, a theme that continues to attract attention across oncology.

Key Factors to Monitor

Investors may follow conference data presentations, clinical enrolment updates, partnering discussions and funding plans.

Clinical development timelines can move as trials progress, so each milestone update is likely to be a focus.

Conclusion

Avacta Group PLC's 10.56% advance on 11 Nov 2026 reflects interest in its clinical pipeline following evidence of proof of mechanism for AVA6103.

With data presentations, candidate selection and further efficacy readouts scheduled, LSE:AVCT has a series of catalysts to follow. Upcoming conference updates and partnering news are the next items to watch.